The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
South East; Berkshire; Buckinghamshire and Oxfordshire
Location of affected unit(s)
Milton Keynes
Sector
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
100 jobs Number of planned job creations
Announcement Date
25 July 2006
Employment effect (start)
Foreseen end date
Description
A company has employed 100 extra staff to make inhaled insulin dispensers for use in the United States. The controversial inhaled drug Exubera, which treats diabetes, has been approved for use in Europe and the US. Hailed as a breakthrough by Diabetes UK, it has been rejected by the NHS for use in the UK on the grounds of cost.
Medical device manufacturer Bespak said its Milton Keynes factory is now almost exclusively geared towards high volume production of the insulin inhaler. Bespak marketing manager Chris Halling said the company now employed about 200 people at its Milton Keynes factory.
Sources
25 July 2006: BBC Website
Citation
Eurofound (2006), Bespak, Business expansion in United Kingdom, factsheet number 63826, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/63826.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
